Guided Therapeutics, Inc. (OTC: QB GTHP) is committed to developing groundbreaking medical devices using our patented biophotonic technology to detect diseases earlier, more accurately, and more efficiently than other tests.
Our products are designed to improve the patient’s experience, provide the physician with more powerful tools, improve the efficiency of the healthcare system and increase shareholder value.
How we are making
a difference globally
Our products are designed to:
Improve the patient’s experience.
Provide the physician with more powerful tools.
Improve the efficiency of the healthcare system.
Our patented technology, which features our flagship product the LuViva® Advanced Cervical Scan, uses biophotonics to detect both physical and chemical changes in tissues that are early signs of cancer.
Cancer screening is a compelling market opportunity proven to save lives. As a pioneering company in this space, GTI represents an excellent investment.
Join our network of Investors
We are actively seeking new investors to join our network. We provide full transparency into our organization and would love to have you join.
We’re international and expanding. Read about Guided Therapeutics
Recent Press Releases
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of LuViva
Nov 09, 2022
Guided Therapeutics Closes $3.3 Million Bridge Financing
Sep 07, 2022
Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
Jul 20, 2022
Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
Mar 31, 2022